Phase I Study of Safety and Pharmacokinetics of Fruquintinib (HMPL-013) in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2016
At a glance
- Drugs Fruquintinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Hutchison MediPharma
- 10 Apr 2013 Final results of this study will be reported at the 2013 American Association for Cancer Research (AACR) Annual Meeting according to a Hutchison MediPharma media release.
- 10 Apr 2013 Status changed from recruiting to completed as reported in a Hutchison MediPharma media release.
- 17 Jul 2012 Planned patient number is 30, official title amended and additional lead trial centre, investigator (Jin Li) identified as reported by ClinicalTrials.gov.